LUCENTIS solution for intravitreal injection 2.3mg/0.23mL [age-related macular degeneration associated with subfoveal choroidal neovascularization]（ルセンティス硝子体内注射液2.3mg/0.23mL［中心窩下脈絡膜新生血管を伴う加齢黄斑変性症］）
Novartis Pharma K.K.
|
The information on this sheet is based on approvals granted by the Japanese regulatory authority. Approval details may vary by country. Medicines have adverse reactions (risks) as well as efficacies (benefits). It is important to minimize adverse reactions and maximize efficacy. To obtain a better therapeutic response, patients should understand their medication and cooperate with the treatment.
|
|
Brand name :
|
LUCENTIS solution for intravitreal injection 2.3mg/0.23mL [age-related macular degeneration associated with subfoveal choroidal neovascularization]
|
|
Active ingredient:
|
Ranibizumab(genetical recombination)
|
|
 |
Effects of this medicine
This medicine inhibits vascular endothelial growth factor (VEGF) which is involved in formation and growth of choroidal neovascular and causes atrophy/loss of choroidal neovascular. As a result, it improves failing vision.
It is usually used to treat age-related macular degeneration associated with subfoveal choroidal neovascularization.
|
Before using this medicine, be sure to tell your doctor and pharmacist
-
If you have previously experienced any allergic reactions (itch, rash, etc.) to any medicines.
If you have: ocular/periocular infections or suspected of them, inflammation within the eye, a history of stroke or transient ischemic attack.
-
If you are pregnant or breastfeeding.
-
If you are taking any other medicinal products. (Some medicines may interact to enhance or diminish medicinal effects. Beware of over-the-counter medicines and dietary supplements as well as other prescription medicines.)
|
Dosing schedule (How to take this medicine)
-
Your dosing schedule prescribed by your doctor is << to be written by a healthcare professional>>
-
In general, administer by intraocular (intravitreal) injection once a month for the 3 months in a row (a total of 3 times). After 3 initial doses, your symptoms and response to the treatment should be assessed monthly, and additional treatment may be given as needed. The treatment interval should be at least 1 month.
-
Depending on your response to the treatment, this medicine may be administered over a long time.
|
Precautions while taking this medicine
-
Since transient blurred vision may occur following the injection, avoid performing dangerous operations such as driving a car or operating machinery until resolution of the symptom.
|
Possible adverse reactions to this medicine
The most commonly reported adverse reactions include ocular inflammation, conjunctival bleeding and elevation of ocular pressure (eye pain, reduced visual acuity). If any of these symptoms occur, consult with your doctor or pharmacist.
The symptoms described below are rarely seen as initial symptoms of the adverse reactions indicated in brackets. If any of these symptoms occur, stop taking this medicine and see your doctor immediately.
-
reduced visual acuity, worsening of bloodshot eyes [retinal bleeding, iatrogenic traumatic cataract, eye disorder such as endophthalmitis]
-
decreased consciousness, one-sided paralysis, slurred speech [stroke]
The above symptoms do not describe all the adverse reactions to this medicine. Consult with your doctor or pharmacist if you notice any symptoms of concern other than those listed above.
|
Storage conditions and other information
|
|
